Literature DB >> 7742036

HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen.

B F Haynes1, M A Moody, C S Heinley, B Korber, W A Millard, R M Scearce.   

Abstract

The extreme variability of HIV-1 immunogenic regions has hampered attempts to design immunogens capable of inducing broadly reactive neutralizing anti-HIV antibody responses. We have begun to study the immune responses generated to a polyvalent mixture of HIV envelope gp120 synthetic peptides, and to determine the ability of each component of a polyvalent immunogen to prime and boost immune responses to each immunogen component. A major concern regarding the use of a polyvalent mixture of HIV-1 immunogens is that the phenomenon of "original antigenic sin," or HIV-1 primer-induced suppression of antibody responses to a subsequent boost by a second HIV-1 variant, may occur and prevent effective anti-HIV immune responses. Using a prototypic four-valent HIV peptide envelope immunogen in BALB/c mice, we observed two types of primer-induced antibody suppression: "original antigenic sin" with primer-induced suppression of antibody responses to only the boosting immunogen, and a second, novel form of primer-induced antibody suppression, with inhibition of antibody responses not only to the priming immunogen but also to all other immunogens in the polyvalent immunogen mixture as well. Importantly, either reversing the sequence of administration of the immunogens or administration of all four components as a polyvalent mixture completely overcame both forms of HIV-1 primer-induced antibody suppression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742036     DOI: 10.1089/aid.1995.11.211

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

Review 1.  HIV vaccine development at Duke University Medical Center.

Authors:  B F Haynes; H X Liao; H F Staats; M S Alam; K J Weinhold; D C Montefiori
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.

Authors:  Eric A Weaver; Zhongjing Lu; Zenaido T Camacho; Fatiha Moukdar; Hua-Xin Liao; Ben-Jiang Ma; Mark Muldoon; James Theiler; Gary J Nabel; Norman L Letvin; Bette T Korber; Beatrice H Hahn; Barton F Haynes; Feng Gao
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence.

Authors:  J D Ahlers; T Takeshita; C D Pendleton; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

5.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

6.  Transcriptional signatures of clonally derived Toxoplasma tachyzoites reveal novel insights into the expression of a family of surface proteins.

Authors:  Terence C Theisen; John C Boothroyd
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

7.  IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells.

Authors:  Maria Blasi; Donatella Negri; Celia LaBranche; S Munir Alam; Erich J Baker; Elizabeth C Brunner; Morgan A Gladden; Zuleika Michelini; Nathan A Vandergrift; Kevin J Wiehe; Robert Parks; Xiaoying Shen; Mattia Bonsignori; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Sampa Santra; Barton F Haynes; Michael A Moody; Andrea Cara; Mary E Klotman
Journal:  Commun Biol       Date:  2018-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.